Cramer: This biotech stock could be worth over $100 billion on an FDA approval
Biogen, with a $54.1 billion market cap, "could be worth twice that if all goes well" with regulators, Jim Cramer says.
Видео Cramer: This biotech stock could be worth over $100 billion on an FDA approval канала CNBC Television
Видео Cramer: This biotech stock could be worth over $100 billion on an FDA approval канала CNBC Television
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Jim Cramer gives his list of stocks that are still cheap with the market at record highs
How to Invest in Biotech Stocks -- Everything You Need to Know
Cathie Woods - Investing in disruptive innovation | SingularityU ExFin South Africa Summit
Tom Lee predicts market will see a strong September, but warns about October
Top 4 Biotech stocks to Buy now (Cathie Wood Portfolio Reveal Genomics Stocks)
Jim Cramer gives a list of winning stocks that he expects will go even higher
🧬 SRNG | Is Ginkgo Bioworks the Next Amazon Stock?
Debt ceiling impact on today's sell-off
Bloomberg Wealth with David Rubenstein: Ron Baron
Watch CNBC's full interview with Berkshire Hathaway CEO Warren Buffett
Jim Cramer's game plan for the trading week of May 10
TIGER 차이나전기차 ETF, 언제까지 성장할 수 있을까?
5 Best Biotech Stocks to Buy for 2021
Jim Cramer's game plan for the trading week of March 22
Cramer's week ahead: Tesla, Microsoft, Starbucks, Facebook and more earnings
Jim Cramer weighs in on whether to buy Square's stock
🚀 12 Stocks That Could 10X Thanks to Palantir (PLTR)
Jim Cramer: How to spot a bottom in the stock market
CNBC's Becky Quick interviews Warren Buffett (2/25/19)
Jim Cramer: 10 tech stocks to buy now in this coronavirus-plagued market